Clinical trialsCompany release

Helus Pharma completes enrolment in Phase 3 APPROACH depression trial; topline still due Q4 2026

Helus Pharma Inc. (HELP) · Mon 16 Nov 2026

Helus Pharma has enrolled 223 patients in its Phase 3 study of HLP003 in major depressive disorder, while quarterly net loss widened to $103.1M.

Helus Pharma Inc. said on 16 November 2026 that it has completed enrolment in APPROACH, its Phase 3 study of HLP003 as an adjunctive treatment for major depressive disorder (MDD). The study enrolled 223 patients, and the company continues to expect topline data in the fourth quarter of 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Helus Pharma Inc. ↗

Article written by VigiEye from the official source (Helus Pharma Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →